Bitter pills: on Court’s intervention, drug pricing

The core issue highlighted is a significant regulatory failure and a loophole in the Drugs (Prices Control) Order, 2013 (DPCO). While the National Pharmaceutical Pricing Authority (NPPA) caps the MRP of scheduled drugs based on market averages, it does not regulate the trade margins (the difference between PTR and MRP) for hospital transactions. This allows hospitals to negotiate a low PTR from manufacturers but still bill patients or the government at the higher capped MRP, pocketing the difference. This structure creates a perverse incentive, effectively functioning as an economic kickback, where hospitals prioritize brands offering the largest profit margins rather than the most affordable options for patients. Furthermore, the Competition Commission of India has noted that tying drug purchases to in-house pharmacies eliminates patient choice and undermines natural market competition. For UPSC, this illustrates the challenges of market regulation in the healthcare sector, where information asymmetry exists between patients and providers, necessitating robust state intervention to protect consumer interests.

The pricing dynamics described demonstrate a clear market failure in the pharmaceutical sector. Unlike typical consumer markets, patients (the end consumers) do not choose their prescription drugs; the choice is made by the hospital or doctor. Therefore, pharmaceutical companies compete for the business of the hospitals, not the patients. To win this business, companies inflate the MRP while offering a low PTR, creating a lucrative spread for the hospital. This pricing strategy disadvantages more affordable, equivalent drugs because they generate less revenue for the healthcare provider. The Supreme Court has suggested a fixed percentage markup across all drugs, but the editorial argues for a regressive margin—where the percentage markup decreases as the drug price increases. This economic tool is designed to neutralize the incentive for sellers to favor disproportionately expensive products. From a macroeconomic perspective, inflated drug prices contribute significantly to Out-of-Pocket Expenditure (OOPE), which is a major driver of medical impoverishment in India.

The societal impact of this pricing structure is severe, particularly concerning the constitutional mandate under Article 21 (Right to Life), which the Supreme Court has interpreted to include the right to health and accessible medical care. The inflated cost of life-saving drugs, such as cancer treatments, places immense financial strain on patients and their families. High costs directly impact treatment adherence, especially for chronic conditions, as patients may ration or abandon expensive regimens they cannot afford. The practice disproportionately affects vulnerable populations who lack comprehensive health insurance, pushing them further into poverty. The intervention by the Supreme Court of India, especially following previous reluctance in similar cases (e.g., Siddharth Dalmia, 2025), underscores the judiciary's role in addressing systemic inequities when the executive and legislative branches fail to implement adequate safeguards. This highlights the ongoing challenge of achieving Universal Health Coverage and ensuring equitable access to healthcare resources in India.